Automated Solutions Available from QIAGEN for Entire Laboratory Workflow
Jan 26 2009

Automated Solutions Available from QIAGEN for Entire Laboratory Workflow

New instruments reduce manual intervention, eliminate need to optimize and facilitate standardization

Palm Springs, Calif. -- Jan. 26, 2009 - Laboratories are now able to automate their entire workflow, from sample to result, with the addition of two new instruments to the QIAGEN portfolio: Rotor-Gene® Q and QIAgilityTM.  Rotor-Gene Q, QIAGEN's real-time PCR cycler, and QIAgility, which enables PCR set-up in a wide range of formats, complete QIAGEN's comprehensive platform of automated solutions. 

Laboratories increasingly are required to analyze a variety of biological samples (such as blood and tissue) using several molecular diagnostic methods. This requires flexible purification solutions that are compatible with downstream processes.  Many labs source their instruments from a variety of companies, and the incompatible formats can lead to inefficiency, data inaccuracies and other complications.  

"With our comprehensive portfolio and complete workflow options, QIAGEN is able to offer our customers something very few of our competitors can - standardization and reliability," says Dr. Wolfgang Leibinger, Global Business Director of Automated Systems at QIAGEN. "This is an absolute necessity when focusing on something as essential as improving human health."

The centrifugal rotary design of the Rotor-Gene Q makes it the most precise and versatile real-time cycler currently available.  The advantages of this instrument are amplified when it is used in conjunction with optimized QIAGEN kits designed for streamlined analysis across a wide range of applications. 

"Our customers have emphasized their need for better solutions for performing DNA and RNA analysis that can help them standardize results and increase productivity in their labs," says Peer Schatz, CEO of QIAGEN.  "We responded by adding these high-performance instruments to our instrument portfolio to offer a complete, automated workflow."

In addition, QIAGEN introduced today the EZ1® Advanced XL - a low-throughput alternative for nucleic acid purification. This new platform is an enhanced version of the already widely used EZ1 Advanced. With the EZ1 Advanced XL, researchers can now process up to 14 samples simultaneously and receive results quickly.

About Rotor-Gene Q

  • Unmatched thermal and optical performance
  • High-resolution melting and fast PCR on one instrument, suitable for many emerging applications
  • Unbreakable tubes and flexible formats
  • Minimal maintenance and calibration requirements, assuring maximum ease-of-use
  • Versatile software package that enables real-time analysis of leading-edge procedures
  • Size/weight: 370 mm (14.6 in.) x 420 mm (16.5 in.) x 275 mm (10.8 in.)/ 14 kg (31 lb.)

About QIAgility

  • Reproducible results for real-time PCR assays
  • Rapid, reliable PCR set-up eliminates manual pipetting steps prone to human error
  • Operated via computer, with easy-to-use software
  • Samples ready for immediate use in downstream applications
  • Size/weight: 53.2 cm (20.9 in.) x 62.6 cm (24.6 in.) without cables x 44.3 cm (17.4 in.) hood closed/41 kg (90.2 lb.) standard configuration.

About EZ1 Advanced XL

  • Easy-to-use workstations, with error-free protocol selection and worktable set-up 
  • Uses proven EZ1 Kits with pre-programmed protocols on EZ1 cards
  • Size/weight: 55.9 cm (27 in.) x 50.9 cm (24 in.) x 50.9 cm (29 in.)/ 58 kg (130 lb.)

More information and pictures are available at



QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at


Share this page